By Sneha S K and Sahil Pandey
Dec 31 (Reuters) - The U.S. Food and Drug Administration has declined to approve Corcept Therapeutics' drug for the treatment of a rare hormonal disorder, the company said on Wednesday.
Shares of the drugmaker were down 48% at $36.41.
The company said the FDA could not arrive at a favorable benefit-risk assessment for the hormone-blocking oral treatment, known as relacorilant, without Corcept providing additional evidence of effectiveness.
The company was seeking approval for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism.
"FDA's request for additional data may require additional trials, significantly dimming Corcept's outlook in Cushings," said Truist analyst Joon Lee.
Hypercortisolism, also known as Cushing's syndrome, occurs when the body is exposed to high cortisol activity.
Corcept had submitted trial data that showed that relacorilant made improvements in a wide array of hypercortisolism's signs and symptoms.
"We will meet with the FDA as soon as possible to discuss the best path forward," said Joseph Belanoff, Corcept's CEO.
Main symptoms of hypercortisolism include a fatty hump between the shoulders, a rounded face, and pink or purple stretch marks on the skin. People with Cushing's also experience diabetes, high blood pressure, muscle weakness and immune suppression.
Relacorilant is a selective cortisol modulator designed to block the effects of cortisol, while avoiding certain off‑target hormonal effects.
"Given the company had opportunities to address FDA's concerns during mid and late-stage reviews, it's unclear if any further dialogue can resolve the review issues without additional trials," Lee added.
Corcept is also studying the drug in a variety of serious disorders including ovarian and prostate cancer. Its other drug known as Korlym is approved to treat high blood sugar caused by hypercortisolism in adults with endogenous Cushing's syndrome.
Other approved treatments for Cushing's syndrome include Isturisa by Recordati and Xeris Biopharma's Recorlev.
(Reporting by Sahil Pandey and Sneha S K in Bengaluru; Editing by Shailesh Kuber)
LATEST POSTS
- 1
Auschwitz Committee wants German auction of Holocaust items scrapped - 2The Best Computer games for Multiplayer Fun
- 3Scientists solve the mystery of 'impossible' merger of 'forbidden' black holes
- 4Science is best communicated through identity and culture – how researchers are ensuring STEM serves their communities
- 5Asia's Noteworthy Destinations: A Voyager's Aide
- Colleges say foreign students feel 'unwelcome' in the U.S. amid big drop in international enrollment, new survey finds
- These are the Fastest Italian Sports Cars
- Role reversal: Ukraine moves training home and exports the lessons abroad
- Aspirin can prevent a serious pregnancy complication — but too few women get it, new report suggests
- 4 injured in suburban Philadelphia nursing home explosion file negligence lawsuit
- SpaceX rocket launches 140 satellites into orbit on Transporter-15, aces landing at sea (video)
- Hundreds show fascist salute at rally in Rome in annual ritual
- New materials, old physics – the science behind how your winter jacket keeps you warm
- The Most Encouraging New companies to Look Out For
